N-((1R,3S)-3-((5-fluoro-2-(5-fluoro-1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-4-yl)amino)cyclohexyl)-2-methoxyacetamide

ID: ALA3317983

Chembl Id: CHEMBL3317983

PubChem CID: 118708556

Max Phase: Preclinical

Molecular Formula: C20H22F2N6O2

Molecular Weight: 416.43

Molecule Type: Small molecule

Associated Items:

Names and Identifiers

Canonical SMILES:  COCC(=O)N[C@@H]1CCC[C@H](Nc2nc(-c3c[nH]c4ncc(F)cc34)ncc2F)C1

Standard InChI:  InChI=1S/C20H22F2N6O2/c1-30-10-17(29)26-12-3-2-4-13(6-12)27-20-16(22)9-25-19(28-20)15-8-24-18-14(15)5-11(21)7-23-18/h5,7-9,12-13H,2-4,6,10H2,1H3,(H,23,24)(H,26,29)(H,25,27,28)/t12-,13+/m1/s1

Standard InChI Key:  CEJXBPHBSKVDCT-OLZOCXBDSA-N

Alternative Forms

  1. Parent:

    ALA3317983

    ---

Associated Targets(non-human)

Influenza A virus (11224 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
PB2 Polymerase basic protein 2 (86 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 416.43Molecular Weight (Monoisotopic): 416.1772AlogP: 2.78#Rotatable Bonds: 6
Polar Surface Area: 104.82Molecular Species: NEUTRALHBA: 6HBD: 3
#RO5 Violations: HBA (Lipinski): 8HBD (Lipinski): 3#RO5 Violations (Lipinski):
CX Acidic pKa: 12.74CX Basic pKa: 2.60CX LogP: 1.95CX LogD: 1.95
Aromatic Rings: 3Heavy Atoms: 30QED Weighted: 0.57Np Likeness Score: -1.22

References

1. Clark MP, Ledeboer MW, Davies I, Byrn RA, Jones SM, Perola E, Tsai A, Jacobs M, Nti-Addae K, Bandarage UK, Boyd MJ, Bethiel RS, Court JJ, Deng H, Duffy JP, Dorsch WA, Farmer LJ, Gao H, Gu W, Jackson K, Jacobs DH, Kennedy JM, Ledford B, Liang J, Maltais F, Murcko M, Wang T, Wannamaker MW, Bennett HB, Leeman JR, McNeil C, Taylor WP, Memmott C, Jiang M, Rijnbrand R, Bral C, Germann U, Nezami A, Zhang Y, Salituro FG, Bennani YL, Charifson PS..  (2014)  Discovery of a novel, first-in-class, orally bioavailable azaindole inhibitor (VX-787) of influenza PB2.,  57  (15): [PMID:25019388] [10.1021/jm5007275]

Source